



Präsentationen

von Studien der SAKK
und der kooperierenden
Gruppen 2024

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ASCO	Poster	SAKK 23/16	Tailored Axillary Surgery with or without Axillary Lymph Node Dissection Followed by Radiotherapy in Clinically Node-Positive Breast Cancer Patients (TAXIS). The OPBC-03/SAKK 23/16 / IBCSG 57-18 / ABCSG-53 / GBG-101 multicenter randomized controlled trial	Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zimmermann F, Montagna G, Fitzal F, Gnani M, Ruhstaller T, Muenst S, Müller A, Lelièvre L, Heil J, Kurzeder C, Egle D, Sávolt A, Heidinger M, Knauer M
	Poster	DANTE	A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness – The IKF633/DANTE Trial, A Trial of AIO in collaboration with SAKK	Al-Batran S, Lorenzen S, Heuer V, Angermeier A, Ettrich TJ, Homann N, Haag GM, Kurreck A, Stein A, Heinemann V, Zander T, Ronellenfitsch U, Kubicka A, Siebenhüner AR, Kopp C, Pauligk C, Goetze TO
	Poster	SAKK 75/08	Whole transcriptome analysis to reveal epithelial-mesenchymal transition after neoadjuvant therapy with or without additional anti-EGFR treatment: Subgroup analysis of esophageal squamous cell carcinomas of the SAKK 75/08 and the EORTC AIO POWER study	Siebenhüner A R, Ruhstaller T, Planas-Paz L, Mühlberger K, Hayoz S, Vassella E, Van Laarhoven HWM, Thuss-Patience PC, Stahl M, Maderer A, Moehler MH, Langer R
	Oral presentation	Ago-Ovar_2.29	Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study	Marmé F, Harter P, Redondo A, Reuss A, Ray-Cocquar I, Lindemann K, Kurzeder C, Nieuwenhuysen E-V, Béllier C, Pietzner K, El-Balat A, Garcia-Duran C, Wimberger P, Pérez-Fidalgo A, Selle F, de Gregorio N, Burges A, Romero I, Hasenburg A, Pautier P
	Oral presentation	ETOP BEAT-meso	BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.	Popat S, Felip E, Dafni U, Pope A, Cedres Perez S, Shah RNH, de Marinis F, Cove Smith L, Bernabe Caro R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Schaer S, Savic Prince S, Roschitzki-Voser H, Ruepp B, Peters S, Stahel RA
	Oral presentation	HD 21	The randomized study GHSG HD21 shows superior tolerability and efficacy of BrECADD versus eBEACOPP in advanced stage classical Hodgkin lymphoma	Borchmann P, Greil R, Schneider G, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Meissner J, Mathas S, Zijlstra JM, Fossa A, Ferdinandus J, Fuchs M, Klapper W, Eich HT, Kobe C, Diehl V
	Poster	SAKK 96/12	Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w)	von Moos R, Müller A, Hayoz S, Mark M, Fischer S, Popescu R, Fehr M, Egger C, Anchisi S, Schmid F, Zaman K, Ackermann CJ, Schreiber A, Bützberger P, Uhlmann Nussbaum C, Küng M, Schär C, Gillessen S, Templeton AJ

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ASCO GU	Poster	SAKK 06/19	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single arm phase 2 trial (SAKK 06/19)	Cathomas R, Spahn M, Hayoz S, Chiquet S, Schneider M, Rentsch CA, Rothschild S I, Petrausch U
ASH	Oral presentation	HD 21	PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial	Ferdinandus J, Kaul H, Foss A, Hüttmann A, Keil F, Ko YD, Hitz F, Schwarz M, Trenker C, Kerkhoff A, Staib P, Wille K, Dresel I, Hahn D, Hertenstein B, Moosmann P, Mey U, Balabanov S, Armytage T, Roncolato F, Christian J, Kreissl S, Fuchs M, Schneider G, Tharmaseelan H, Eichenauer DA, von Tresckow B, Borchmann P, Bröckelmann PJ
	Oral presentation	TRIANGLE	Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project	Ladetto M, Gutmair K, Doorduijn JK, Gine E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Stefani PM, Horowitz NA, Gomes da Silva M, Leppä S, Jiang L, Pott C, Klapper W, Schmidt C, Unterhalt M, Dreyling M, Hoster E
	Oral presentation	TRIANGLE	Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network	Dreyling M, Doorduijn JK, Gine E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Donnarumma D, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Pott C, Klapper W, Schmidt C, Unterhalt M, Ladetto M, Hoster E
	Poster	SAKK 38/19	Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations	Romano I, Marques De Almeida J, Terzi Di Bergamo L, Brusca A, Schaer S, Moia R, Piffaretti D, Piroso MC, Concoluci A, Forestieri G, Jauk F, Salehi M, Galimberti GA, Bocchetta S, Bertoni F, Novak U, Hitz F, Dirnhofer S, Musilova J, Fuhrer A, Hayoz S, Ceriani L, Gaidano G, Stathis A, Zucca E, Rossi D
EHA	Oral presentation	HOVON 102, HOVON 103, HOVON 132	Adverse Prognostic Impact of Secondary-Type Mutations in ELN 2022 Favorable Risk Acute Myeloid Leukemia	Kotsos D, Boertjes E, Gradowska P, Pabst T, Maertens J, Manz M, Beverloo B, Valk PJM, Jansen JJWM, Ossenkoppele G, Löwenberg B, Huls G, Versluis J
	Poster	HOVON 102, HOVON 103, HOVON 132	Liposomal cytarabine and daunorubicin (CPX-351) versus standard intensive induction chemotherapy in patients with therapy-related AML or AML with MDS-related changes: a comparative HOVON-SAKK analysis	Kotsos D, Gradowska P, Hermans S, Pabst T, Maertens J, Manz M, Beverloo B, Jansen JJWM, Ossenkoppele G, Löwenberg B, Huls G, Raaijmakers MHGP, Versluis J

Konferenz	Art der Präsentation	Studie	Titel	Autoren
EHA	Poster	HOVON 135	CD34 ⁺ CD38 ⁻ Leukemia Stem Cells are Associated with Prognosis in Non-Intensively Treated Acute Myeloid Leukemia	Reuvekamp T, Ngai LL, den Hartog D, Carbaat-Ham J, Oudshoorn-van Marsbergen L, Fayed MMHE, Sullivan AM, Scholten WJ, Kelder A, Snel AN, Mocking TR, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Breems D, van Lammere-venema D, Boersma R, Ossenkoppele GJ, van de Loosdrecht AA, Bachas C, Huls G, de Leeuw DC, Cloos J
	Poster	SAKK 34/17	Ibrutinib lead-in followed by venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia	Condoluci A, Pini K, Stüssi G, Müller G, Dietrich D, Cantoni A, Cathomas R, Mey U, Widmer A, Zenz T, Gregor M, Heim D, Andres M, Benz R, Rossi D
	Oral presentation	HD 21	Gonadal Function Recovery and Fertility in the Phase III German Hodgkin Study Group HD21 trial	Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Robertz AS, Rosenbrock J, Fuchs M, Borchmann P, Behringer K
	Oral presentation	HD 21	The randomized study GHSG HD21 shows superior tolerability and efficacy of BRECAD versus BEACOPP in advanced stage classical hodgkin lymphoma	Borchmann P, Moccia A, Greil R, Schneider G, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fossa A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Ferdinandus J, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Hallek M, Dietlein M, Kobe C, Diehl V
ELCC	Poster	SAKK 16/XX not operated	Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.	Cardoso Almeida S, Schär S, Hayoz S, Guckenberger M, Finazzi T, Opitz I, Schmid S, Mark M, Addeo A, Mauti LA, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D
ERS	Oral presentation	SAKK 16/14	Characterizing the tumor microbiome of non-small cell lung cancer patients treated with neoadjuvant chemo-immunotherapy (SAKK 16/14)	Boesch M, Baty F, Rothschild S, Alborelli I, Keller E, Savic S, Hayoz S, Jörger M, Früh M, Brutsche M
ESCCA	Oral presentation	HOVON 135	CD34 ⁺ CD38 ⁻ Leukemia Stem Cells are Associated with Prognosis in Non-Intensively Treated Acute Myeloid Leukemia	Reuvekamp T, Ngai LL, den Hartog D, Carbaat-Ham J, Oudshoorn-van Marsbergen L, Fayed MMHE, Sullivan AM, Scholten WJ, Kelder A, Snel AN, Mocking TR, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Breems D, van Lammere-venema D, Boersma R, Ossenkoppele GJ, van de Loosdrecht AA, Bachas C, Huls G, de Leeuw DC, Cloos J
ESGO	Oral presentation	ENGOT-en7_AtTEnd	ATTEND/ENGOT-EN7: Phase III double blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma	Colombo N, Harano K, Hudson R, Galli F, Antill Y, Choi C-H, Rabaglio M, Marmé F, Petru E, Lai C-H, Biagioli E, Fariñas-Madrid L, Takehara K, Allan K, Lee Y-C, Piovano E, Zamagni C, Tasca G, Ferrero A, Barretina-Ginesta M-P

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ESGO	Oral presentation	ENGOT-en7_AtTEnd	Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of AtTEnd/ENGOT-EN7 trial	Nishio S, Pardo B, Hudson E, Rulli E, Antill Y, Lee C, Rabaglio M, Heitz F, Leitner K, Lai C-H, Uggeri S, Manso L, Harano K, Allan K, Lee YC, Tognon G, Canova S, Petrella MC, Gadducci A, Colombo N
ESMO	Poster	SAKK 21/18	Cardiovascular events related to CDK4/6 inhibitors: a systematic review and safety meta-analysis of randomized controlled trials	Boismoreau L, Dolladille C, Bastien E, Morice PM, Emile G, Ruhstaller T, Alexandre J, Da Silva A
	Oral presentation	SAKK 41/13	Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial	Güller U, Hayoz S, Horber D, De Dosso S, Köberle D, Schacher S, Inauen R, Stahl M, Delaunoy T, Ettrich T, Bodoky G, Michel P, Kössler T, Rothgiesser K, Calmonte S, Jörger M
	Poster	SAKK 15/19	Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC) – a multicenter single-arm open label phase II trial (SAKK 15/19)	Addeo A, Dietrich D, Mach N, Mark MT, Jörger M, Froesch P, Wannesson L, König D, Fernandez E, Patzen A, Veesh H, Picardi C, Früh M
	Poster	SAKK 16/XX Gender	Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14	Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti L, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Beat Ris H, Özdemir BC, Schmid S
	Oral presentation	STAMPEDE	Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE	Gillessen S, Murphy LR, James ND, Sachdeva A, Attard G, Jones RJ, Adler A, El-Taji O, Varughese M, Gale J, Brown SJ, Srihari NN, Millman R, Matheson D, Amos CL, Murphy C, McAlpine C, Parmar MK, Brown LC, Clarke N
	Poster	SAKK Services	Lack of Abscopal effect and Radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy	Meisel A, Von Moos R, Haider A, Holer L, Hayoz S, Bengs S, Treyer V, Abedian R, Websky S, Sacha I, Rothschild SI, Hochmair M;J, Gandara D R, Capuzzo F, Reck M, Frank Stenner-Liewen F, Mark MT
ESTRO	Oral presentation	ETOP CHESS	Multimodality treatment in synchronous oligometastatic NSCLC: final analysis of the ETOP CHESS trial	Guckenberger M, Opitz I, Dellaport MT, Curioni-Fontecedro A, Frauenfelder T, Cerciello F, Sullivan I, Hendriks L, Dorta M, Callejo A, Aerts J, Addeo A, Dingemans A-M, Pasello G, Provencio M, Ribi K, de Marinis F, Mederos N, Roschitzki-Voser H, Ruepp B, Kammler R, Tsourti Z, Peters S, Stahel R

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ESTRO	Oral presentation	SAKK 16/18	SAKK16/18: Quality assurance and interim safety of neoadj. immune-modulatory RT in st. III(N2) NSCLC	Finazzi T, Holer L, Tang H, Riesterer O, Allal A, Elicin O, Glatzer M, Durham A, Martucci F, Adam L, Mosna-Firlejczyk K, Bettini A, König D, Häfliger S, Früh M, Janthur W, Addeo A, Froesch P, Mark M, Scheibe B, Dorn P, Savic-Prince S, Rothschild SI, Guckenberger M, Mauti LA
	Posterdiskussion	SAKK 09/10	Implementation of PSMA-PET/CT improves treatment outcomes after salvage radiotherapy for recurrent or persistent prostate cancer after surgery	Zamboglou C, Staus P I, Wolkewitz M, Schmidt Hegemann N, Wiegel T, Emmett L, Fanti S, Grosu A L, Koerber S, Kroeze S, Ceci F, Peeken J, Hayoz S, Abersold D M, Vrachimis A, Ghadjar P
ESTS	Oral presentation	SAKK 16/14	Perioperative Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer – Five-year survival and surgical outcomes of the multicenter single-arm phase II trial SAKK 16/14	Gonzalez M, Opitz I, Hayoz S, Chiquet S, Zippelius A, Bettini A, Früh M, Lardinois D, Gelpke H, Britschgi C, Peters S, Mark M, Ochsenbein AF, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Pless M, Rothschild SI
SABCS	Poster	SAKK 66/22	Evaluation of Pathological Complete Response (pCR) and Immunomodulatory Effects Following Intratumoral (IT) Injection of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer (TNBC): A Phase II Randomized Study, the INVINCIBLE-4-SAKK Trial. NCT06358573	Zürcher-Härdi U, Müller A, Calcinotto A, Varga Z, Marcon M, Tredan O, Gysel K, Eckhardt K, Charles R, Bender LH, Jörgen M,
	Posterdiskussion	SAKK 96/12	Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)	Müller A, Templeton A J, Hayoz S, Ursina Zürcher U, Hasler-Strub U, Schwitzer M, Nothelfer T, Dedes K, Zaman K, Küng M, Rossi L, Schreiber A, Fehr M, Güller U, Vetter M, Popescu R, Weder P, Inauen R, Uhlmann Nussbaum C, Claudine Egger C, Cescato C, Seifert B, Thorn D R, Schär C, Gilles-S, von Moos R
SOHC	Oral presentation	SAKK 41/13	Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial	Güller U, Hayoz S, Horber D, De Dosso S, Köberle D, Schacher S, Inauen R, Stahl M, Delaunoy T, Ettrich T, Bodoky G, Michel P, Kössler T, Rothgiesser K, Calmonte S, Jörgen M
	Oral presentation	SAKK 16/14	Perioperative Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer – Final analysis of the multicenter single-arm phase II trial SAKK 16/14	Rothschild S I, Zippelius A, Hayoz A, Chiquet S, Savic Prince S, Bettini A, Früh M, Jörgen M, Lardinois D, Gelpke H, Opitz I, Britschgi C, Mauti L A, Peters S, Mark M, Cathomas R, Ochsenbein A F, Janthur W-D, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Gonzalez M, M. Pless
	Oral presentation	SAKK 96/12	Osteonecrosis of the jaw (ONJ) in patients with bone metastases treated with denosumab every 4 vs. 12 weeks (randomized phase 3 trial; SAKK 96/12)	von Moos R, Müller A, Hayoz S, Mark M, Fischer S, Popescu R, Fehr M, Egger C, Anchisi S, Schmid F, Zaman K, Ackermann C J, Schreiber A, Bützberger P, Uhlmann Nussbaum C, Küng M, Schär C, Gilles-S, Templeton AJ

Konferenz	Art der Präsentation	Studie	Titel	Autoren
SSDV	Poster	SAKK services	Differences in survival of melanoma patients after immune checkpoint inhibitor discontinuation for response or toxicity – a single center analysis by patient sex	Özdemir B, Herren M, Zahn C, Ryser C, Bill R, Gysel K, Cerciello F
SSP	Oral presentation	SAKK 16/14	The tumor-co-localized microbiome of non-small cell lung cancer treated with neoadjuvant sequential chemo-immunotherapy – an observational feasibility study (SAKK 16/14)	Boesch M, Baty F, Rothschild S, Alborelli I, Keller E, Savic S, Hayoz S, Jörger M, Früh M, Brutsche M
WCLC	Oral presentation	SAKK 17/18	Circulating protein signatures and immune cell subtypes as predictive biomarkers in patients with NSCLC from the SAKK 17/18 ORIGIN trial	Rigutto A, Feng Y, Shihkova P, Räss L, Schär S, Bruderer R, Tognetti M, Jörger M, Hayoz S, Somasundaram V, Nuñez N, Fournier N, Lourenço J, Gottardo R, Becher B, Addedo A, Gupta A, Curioni-Fontecedro A